1.
Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford). 2004;43(2):229-233. doi:10.1093/rheumatology/keg480
2.
Martins-Rocha T, Matias JP, Vicente Ferreira M, Mota B, Brito I. Post-infectious digital ischemia successfully treated with iloprost in a child. Reumatol Clin (Engl Ed). 2020;16(5 Pt 1):364-365. doi:10.1016/j.reuma. 2018.05.003
3.
Meini S, Dentali F, Melillo E, de Donato G, Mumoli N, Mazzone A. Prostanoids for critical limb ischemia: a clinical review and consideration of current guideline recommendations. Angiology. 2020;71(3):226-234. doi:10.1177/0003319719889273
4.
Boga M. Acute limb ischemia. Turk J Family Pract. 2009;13(1):11-15. doi: 10.54308/tahd.2024.802
5.
Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-38. doi:10.1016/s0741-5214(97)70045-4
6.
Lerner A, Reis D, Soudry M. Primary Treatment. In: Severe Injuries to the Limbs. Springer, Berlin, Heidelberg. 2007, p. 5-11.
7.
Meini S, De Franco V, Auteri A, Setacci C, Di Renzo M, Pieragalli D. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV). Int Angiol. 2005;24(1):64-69.
8.
García Soler P, Milano Manso G, Camacho Alonso JM, Manuel González J. Iloprost para el tratamiento de la isquemia digital en el shock séptico pediátrico. Med Clin (Barc). 2011;136(15):695-696. doi:10.1016/j.medcli. 2009.12.012
9.
Tanyildiz M, Ozden O, Ozbek L, et al. Management of an earthquake in a pediatric intensive care unit. J Child. 2023; 23(3): 21-30. doi:10.26650/jchild.2023.1341364
10.
Watson HR, Smith FCT, Shearman P, Hildebrand M. Pharmacokinetics and pharmacodynamics of intra-graft iloprost in femorodistal bypass surgery. Prostagl Leukotrien Essent Fatty Acids. 1997;56(5):389-393. doi: 10.1016/s0952-3278(97)90589-5
11.
Müler B, Krast T, Stürzebecher S, Witt W, Schillinger E, Baldus B. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease. Acta Biomed Biochim. 1988; 47(10-11):S40-S44.
12.
Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs. 1992;43(6):889-924. doi:10.2165/00003495-199243060-00008
13.
Caspary L, Creutzig A, Alexander K. Intravenous infusion iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation. Eur J Clin Pharmacol. 1991;41(2):131-136. doi:10.1007/BF00265905
14.
Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. 2003;88(7):601-607. doi:10. 1136/adc.88.7.601
15.
Rooke TW, Hirsch AT, Misra S, et al. American College of Cardiology Foundation Task Force; American Heart Association Task Force. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004
16.
Montorfano MA, Montorfano LM, Perez Quirante F, Rodríguez F, Vera L, Neri L. The FAST D protocol: a simple method to rule out traumatic vascular injuries of the lower extremities. Crit Ultrasound J. 2017;9(1):8. doi: 10.1186/s13089-017-0063-2